Mirum Pharmaceuticals (NASDAQ: MIRM) and FarmaMondo entered into an exclusive distribution and supply agreement appointing the FarmaMondo Group as the exclusive partner to make their innovative product Maralixibat available for Patients in Russia and CIS countries.
Maralixibat is an orally administered medication in clinical development (pre-registration in FDA and P2 in EU) for children with rare liver diseases: Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and biliary atresia. The agreement appoints FarmaMondo as the exclusive partner of Mirum in the territory for both MAP and MA rights and it brings great hope for many patients in the region who may gain therapeutic options when other alternative do not currently exist for their life-threatening disease.
The agreement represents the consistent trust of the industry in the FarmaMondo Group as an attractive commercial partner for innovative specialty biopharma companies. It reinforces the FarmaMondo vision as a global pharmaceutical specialty access company and it is a valued addition to its promising portfolio of products.
FarmaMondo is a Swiss-headquartered pharmaceutical group focused on providing market access and specialty distribution services, through a unique infrastructure and geographical footprint targeted to providing access to medicines across unlicensed and licensed phases.
For more information about FarmaMondo please visit: www.farmamondo.com.
Mirum is developing transformative medicines for rare cholestatic liver diseases, including Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), biliary atresia (BA), primary sclerosing cholangitis (PSC) and intrahepatic cholestasis of pregnancy (ICP), and primary biliary cholangitis.
Working closely with patients and caregiver communities, Mirum understands the challenges of living with cholestatic liver diseases. Based on a wealth of data from clinical trials spanning many years and patients, the Mirum approach can address the underlying cause of symptoms and liver damage.
For more information about Mirum Pharmaceuticals please visit: www.mirumpharma.com